Missing Data and Measurement Variability in Assessing Progression-Free Survival Endpoint in Randomized Clinical Trials
暂无分享,去创建一个
[1] P. Keegan,et al. Review of oncology and hematology drug product approvals at the US Food and Drug Administration between July 2005 and December 2007. , 2010, Journal of the National Cancer Institute.
[2] Lori E Dodd,et al. Measurement error in the timing of events: effect on survival analyses in randomized clinical trials , 2010, Clinical trials.
[3] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[4] L. Schwartz,et al. Lessons learned from independent central review. , 2009, European journal of cancer.
[5] J. Denne,et al. Attenuation of treatment effect due to measurement variability in assessment of progression‐free survival , 2012, Pharmaceutical statistics.
[6] L. Dodd,et al. Assessment of Audit Methodologies for Bias Evaluation of Tumor Progression in Oncology Clinical Trials , 2013, Clinical Cancer Research.
[7] S. Mandrekar,et al. Impact of disease progression date determination on progression‐free survival estimates in advanced lung cancer , 2012, Cancer.
[8] Jon A. Wellner,et al. A Hybrid Algorithm for Computation of the Nonparametric Maximum Likelihood Estimator from Censored Data , 1997 .
[9] B. Freidlin,et al. Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Boris Freidlin,et al. Overall survival as the outcome for randomized clinical trials with effective subsequent therapies. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Daniel J. Sargent,et al. Role of sensitivity analyses in assessing progression-free survival in late-stage oncology trials. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Suman Bhattacharya,et al. An Audit Strategy for Progression‐Free Survival , 2011, Biometrics.
[13] D J Sargent,et al. Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group. , 2011, European journal of cancer.
[14] J. Helterbrand,et al. Blinded independent central review of progression in cancer clinical trials: results from a meta-analysis. , 2011, European journal of cancer.
[15] Huanyu Chen,et al. Evaluation of Blinded Independent Central Review of Tumor Progression in Oncology Clinical Trials: A Meta-analysis , 2013, Therapeutic innovation & regulatory science.
[16] Jianguo Sun,et al. The Statistical Analysis of Interval-censored Failure Time Data , 2006 .
[17] R. Little,et al. The prevention and treatment of missing data in clinical trials. , 2012, The New England journal of medicine.
[18] Binsheng Zhao,et al. The Imaging Viewpoint: How Imaging Affects Determination of Progression-Free Survival , 2013, Clinical Cancer Research.
[19] Xingqiu Zhao,et al. Generalized Log‐Rank Tests for Interval‐Censored Failure Time Data , 2005 .